SCHEMBL2086426

SCHEMBL2086426

CCOC(=O)c1c(O)c2nc(OC)ccc2n(Cc2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.51
GAA P10253 3/20 0.49
LMNA P02545 3/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
ALDH1A1 P00352 7/20 0.48
HPGD P15428 3/20 0.48
CASP1 P29466 3/20 0.48
CASP7 P55210 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
FEN1 P39748 2/20 0.47
MAPK1 P28482 2/20 0.45
USP2 O75604 1/20 0.45
GLA P06280 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RECQL P46063 1/20 0.44
HTT P42858 1/20 0.44
TDP2 O95551 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1522907 0.82 KDM4E (0.57) KDM4EGAALMNAMAPTPKM
SCHEMBL2086562 0.82 EGLN1 (0.61) KDM4E
SCHEMBL1522936 0.78 KDM4E (0.81) KDM4EGAALMNAMAPTPKM
SCHEMBL5331127 0.77 KDM4E (0.58) KDM4EGAALMNAMAPTPKM
SCHEMBL4854903 0.77 FEN1 (0.58) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL4754692 0.77 ALDH1A1 (0.65) KDM4EGAALMNAMAPTPKM
SCHEMBL2088737 0.77 KDM4E (0.52) KDM4EGAALMNAMAPTPKM
SCHEMBL14607234 0.76 ALDH1A1 (0.62) KDM4EGAALMNAMAPTPKM
SCHEMBL5529505 0.76 ALDH1A1 (0.81) KDM4EGAALMNAMAPTPKM
SCHEMBL1522548 0.75 KDM4E (0.59) KDM4EGAALMNAMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897612-B2 Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors GlaxoSmithKline, LLC (US) 2011-03-01 US disclosed
US-20090082357-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2009-03-26 US disclosed
US-20070213335-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082357-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KDM4E 566/4885GAA 144/4885LMNA 3318/4885
US-20070213335-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KDM4E 566/4885GAA 144/4885LMNA 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.